Simmons Anthony, Whitehead Robert P, Kolokoltsov Andrey A, Davey Robert A
Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Virol J. 2006 Feb 28;3:8. doi: 10.1186/1743-422X-3-8.
Genetic redirection of lymphocytes that have been genetically engineered to recognize antigens other than those originally programmed in their germlines is a potentially powerful tool for immunotherapy of cancers and potentially also of persistent viral infections. The basis for this procedure is that both cancers and some viruses have developed strikingly similar mechanisms of evading attacks by host immune mechanisms. To redirect human peripheral blood lymphocytes (PBLs) with a chimeric T cell receptor (chTCR) so that they recognize a new target requires a high degree of transfection efficiency, a process that is regarded as technically demanding.
Infection with a retroviral vector carrying a chTCR cassette was shown to transduce 100% of rapidly dividing murine T cells but typically, only approximately 10% of PBLs could be infected with the same vector. In contrast with other retroviruses, lentiviruses integrate their genomes into non-dividing cells. To increase host cell range, vesicular stomatitis virus G protein was pseudotyped with a lentivirus vector, which resulted in approximately 100% PBL transduction efficiency. Signaling of PBLs bearing chimeric receptors was shown by specific proliferation on exposure to cells expressing cognate ligand. Further, T-bodies against CEA showed a startling ability to cause regression of malignant colon tumors in a nude mouse model of human cancer.
A lentivirus/VSV pseudotyped virus, which does not require replicating cells for integration of its genome, efficiently transduced a high proportion of human PBLs with chTCRs against CEA. PBLs transduced by infection with a lentivirus/VSV pseudotyped vector were able to proliferate specifically in vitro on exposure to CEA-expressing cells and further they had a startling therapeutic effect in a mouse model of human colon cancer.
对淋巴细胞进行基因改造,使其识别除种系中最初编码的抗原以外的其他抗原,这种基因重定向是癌症免疫治疗以及潜在的持续性病毒感染免疫治疗的一种潜在有力工具。该方法的基础是癌症和一些病毒都已形成了与宿主免疫机制逃避攻击极为相似的机制。要通过嵌合T细胞受体(chTCR)重定向人类外周血淋巴细胞(PBL),使其识别新的靶标,需要高度的转染效率,这一过程在技术上被认为具有挑战性。
携带chTCR盒的逆转录病毒载体感染可转导100%快速分裂的小鼠T细胞,但通常同一载体只能感染约10%的PBL。与其他逆转录病毒不同,慢病毒将其基因组整合到非分裂细胞中。为了扩大宿主细胞范围,用慢病毒载体对水疱性口炎病毒G蛋白进行假型包装,这导致了约100%的PBL转导效率。携带嵌合受体的PBL在暴露于表达同源配体的细胞时通过特异性增殖显示出信号传导。此外,针对癌胚抗原(CEA)的T体在人癌裸鼠模型中显示出惊人的使恶性结肠肿瘤消退的能力。
一种慢病毒/水疱性口炎病毒假型病毒,其基因组整合不需要复制细胞,能有效地用针对CEA的chTCR转导高比例的人类PBL。通过慢病毒/水疱性口炎病毒假型载体感染转导的PBL在暴露于表达CEA的细胞时能够在体外特异性增殖,并且在人结肠癌小鼠模型中具有惊人的治疗效果。